Not exact matches
Patisiran was being evaluated in a late - stage study
against a
placebo for the
treatment of patients with hereditary ATTR (hATTR) amyloidosis with polyneuropathy.
Bone loss was higher in men compared to women in the
placebo arm, and the protection
against bone loss was higher in men than in women in the
treatment arm.
Those studies really seek to make sure that the drug is safe, and if a drug passes that Phase I safety trial they move on to a Phase II trial, where that drug is compared
against a
placebo — so, no
treatment or an existing drug to see if it performs as well or better than the existing drug.
For this reason, scientists believe it best to compare any
treatment against a
placebo rather than a no -
treatment group.